Top

Published in:

01-06-2013 | Original Article

How do we approach the goal of identifying everybody with Lynch Syndrome?

Authors: Heather Hampel, Albert de la Chapelle

Published in: Familial Cancer | Issue 2/2013

Excerpt

Lynch syndrome (LS) is the most common inherited cause of colorectal (CRC) and endometrial cancer. We here define LS as an individual with a germline deleterious mutation in one of the four mismatch repair (MMR) genes MSH2, MLH1, MSH6 and PMS2 or EPCAM [1]. Presently, most people diagnosed with LS have already had colorectal (CRC) endometrial (EC) or other LS-associated cancers; however, among all existing carriers of LS the majority has not (yet) had cancer. LS is currently seriously under-diagnosed. A recent study [2] of stages III and IV CRC patients in the Kaiser Permanente healthcare system found that family history documentation varied from site to site with 3 sites documenting family history on <70 % of cases and 4 sites documenting family history in over 85 % of cases. Despite the fact that in those with a documented family history, 61 % had a relative with cancer and 20 % of these had CRC in at least one first degree relative, <5 % of the population received any Lynch syndrome testing [2]. There are essentially three different approaches that can be taken to identify individuals with Lynch syndrome: (1) The current approach which is to educate providers about Lynch syndrome and then expect that they take a family history from their patients and refer appropriate patients for a cancer genetics evaluation; (2) screen all newly diagnosed CRC and EC patients for Lynch syndrome at the time of diagnosis; or (3) screen the general public for Lynch syndrome either at birth or in early adulthood. Since it is clear that the current approach is not sufficient alone, we discuss the latter two approaches here. …

Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985PubMedCrossRef

Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H et al (2012) PS1-08: lynch syndrome screening pattering in colorectal cancer patients in a large multi-institutional cohort. Clin Medi Res 10(3):146CrossRef

Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. WHO, Geneva. Available from: http://www.who.int/bulletin/volumes/86/4/07-050112BP.pdf

Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF et al (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1):9–22CrossRef

de la Chapelle A (2005) The incidence of Lynch syndrome. Fam Cancer 4(3):233–237PubMedCrossRef

Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M et al (2011) Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305(22):2304–2310PubMedCrossRef

Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135(2):419–428PubMedCrossRef

Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21):1481–1487PubMedCrossRef

Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354(26):2751–2763PubMedCrossRef

10.

Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58(15):3455–3460PubMed

11.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788PubMedCrossRef

12.

Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRef

13.

Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994PubMedCrossRef

14.

Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18(11):2193–2200PubMed

15.

Society AC (2012) Cancer treatment and survivorship facts & figures 2012–2013. Am Cancer Soc, Altanta

16.

Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65PubMedCrossRef

17.

Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S et al (2012) Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: national Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 21(4):484–493PubMedCrossRef

18.

Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12):1507–1517PubMedCrossRef

19.

NCCN (2012) National Comprehensive cancer network clinical practice guidelines in oncology: colorectal cancer screening; V.2.2012. http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf

20.

Vasen HF, de Vos Tot Nederveen Cappel WH (2006) An evidence-based review on surveillance for Lynch syndrome. Dis Colon Rectum 49(11):1797–1798 (author reply 9)

21.

Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27(28):4793–4797PubMedCrossRef

22.

Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef

23.

Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRef

24.

Recommendations from the EGAPP Working Group (2009) genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41CrossRef

25.

Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN et al (2012) Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30(10):1058–1063PubMedCrossRef

26.

Porteous M, Dunckley M, Appleton S, Catt S, Dunlop M, Campbell H et al (2003) Is it acceptable to approach colorectal cancer patients at diagnosis to discuss genetic testing? A pilot study. Br J Cancer 89(8):1400–1402PubMedCrossRef

Title: How do we approach the goal of identifying everybody with Lynch Syndrome?
Authors: Heather Hampel
Albert de la Chapelle
Publication date: 01-06-2013
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 2/2013
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-013-9611-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2013

Foreword for “100 years of Lynch syndrome”

Lynch syndrome: the patients perspective

Surveillance for urinary tract cancer in Lynch syndrome

Genetic modifiers of cancer risk in Lynch syndrome: a review

Colorectal surveillance in Lynch syndrome families

Prediction models in Lynch syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer